Why is target trial emulation not being used in health technology assessment real-world data submissions?

RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16

“…There are however some minor differences – for example, single-world intervention graphs are not mentioned in guidance from the National Institute for Health and Care Excellence (NICE) or Canada's Drug Agency (formerly CADTH) [ 7 , 8 ]. Whether or not the target trial framework is the framework used, what is crucial is that there is transparency in all aspects of conducting a study – from choosing a data source to analyzing the results [ 9 ]. It remains to be seen if there ends up being a preference by decision makers for one causal framework over another, and whether or not the individual nuances of guidance differences between HTA agencies and regulators impacts acceptance of RWE.…”